Leveraging the Ubiquitin-Proteasome System to Modulate the Undruggable Proteome
Nurix Therapeutics is a clinical-stage biopharmaceutical leader specializing in the targeted modulation of protein levels through the ubiquitin-proteasome system. By 2026, their proprietary DELIGASE platform has evolved into a highly automated, AI-augmented engine for discovering small molecules that either degrade or stabilize specific proteins. The platform utilizes massive DNA-encoded libraries (DEL) combined with machine learning to predict ligand-protein binding interactions with unprecedented precision. This technical architecture allows Nurix to target 'undruggable' proteins—those lacking traditional active sites—by recruiting E3 ligases to trigger natural cellular degradation. Their market position is defined by a hybrid model of internal drug development and high-value strategic partnerships with giants like Gilead and Sanofi. Technically, the 2026 iteration of the platform integrates structural biology, computational chemistry, and high-throughput screening data into a unified predictive model, significantly reducing the 'hit-to-lead' timeline in oncology and autoimmune therapeutic discovery.
Nurix Therapeutics is a clinical-stage biopharmaceutical leader specializing in the targeted modulation of protein levels through the ubiquitin-proteasome system.
Explore all tools that specialize in e3 ligase mapping. This domain focus ensures Nurix Therapeutics DELIGASE Platform delivers optimized results for this specific requirement.
Explore all tools that specialize in analyze genomic data to find potential drug targets. This domain focus ensures Nurix Therapeutics DELIGASE Platform delivers optimized results for this specific requirement.
A discovery engine that couples DNA-encoded libraries (DEL) with a vast collection of E3 ligases.
Bifunctional small molecules designed to bring an E3 ligase and a target protein into close proximity.
A proprietary database and physical library of over 600 E3 ligases with mapped functional profiles.
Deep learning models that extrapolate DEL screening data to identify novel scaffolds not present in the physical library.
Inhibiting E3 ligases to prevent the degradation of beneficial proteins.
Automated pipeline for decoding DNA tags from affinity-selection assays to identify binders.
Utilizing cryo-EM and X-ray crystallography data to guide molecular docking simulations.
Therapeutic area alignment and target protein selection.
Computational feasibility study using AI-driven binding site analysis.
Custom DNA-encoded library (DEL) synthesis for the specific target.
High-throughput screening against the DELIGASE ligase collection.
Machine learning refinement of 'hits' to identify high-affinity ligands.
Medicinal chemistry optimization of Chimeric Targeting Molecules (CTMs).
In vitro validation of protein degradation or stabilization efficiency.
Pharmacokinetic and pharmacodynamic (PK/PD) profiling in cellular models.
Selection of Development Candidate (DC) for IND-enabling studies.
Transition to clinical trial phase and regulatory submission.
All Set
Ready to go
Verified feedback from other users.
"Highly regarded in the biotech industry for its scientific rigor and successful execution of protein degradation targets. Partners praise the platform's versatility."
Post questions, share tips, and help other users.
Augmenting human intelligence to discover and develop life-changing medicines via end-to-end AI drug discovery.